論文

査読有り
2013年7月

A Novel Prodrug Strategy for Extremely Hydrophobic Agents: Conjugation to Symmetrically Branched Glycerol Trimer Improves Pharmacological and Pharmacokinetic Properties of Fenofibrate

MOLECULAR PHARMACEUTICS
  • Licht Miyamoto
  • Masashi Watanabe
  • Chiaki Taoka
  • Mai Kono
  • Yosuke Tomida
  • Tsuyoshi Matsushita
  • Masaki Kamiya
  • Hatsuhiko Hattori
  • Keisuke Ishizawa
  • Shinji Abe
  • Hisao Nemoto
  • Koichiro Tsuchiya
  • 全て表示

10
7
開始ページ
2723
終了ページ
2729
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1021/mp400133j
出版者・発行元
AMER CHEMICAL SOC

Management of a lipophilic hydrophilic balance is a key element in drug design to achieve desirable pharmacokinetic characters. Therefore we have created unique modular molecules, symmetrically branched oligoglycerols (BGL), as an alternative way to endow hydrophobic Molecules with sufficient hydrophilicity. We have successfully demonstrated amelioration of the water solubility and thermal stability of several hydrophobic agents by covalent conjugation to BGL, so far. However, it has not been clarified whether the molecular modification by BGL, also improves the pharmacological and/or pharmacokinetic properties indeed. Recently, we synthesized a novel BGL-Prodrug derivative of fenofibrate, which is an antihyperlipidemic agent and one of the most hydrophobic medicinal compounds currently used clinically, by conjugating fenofibric acid to symmetrically branched glycerol trimer (BGL003), the simplest BGL. We have previously demonstrated that the hydrophilicity and water solubility of fenofibrate are improved more than 2000 times just by conjugation to the BGL003 T verify our hypothesis that the prodrug strategy with BGL should improve pharmacological efficacy and pharmacokinetic properties of extremely hydrophobic agents such as fenofibrate by the rise in hydrophilicity, we evaluated the BGL003-prodrug derivative of fenofibrate (FF-BGL) using rodent models. Here we demonstrate that the lipid-lowering effects of fenofibrate are much potentiated by chemical conjugation to BGL003 without exhibiting significant toxicity. Plasma concentration of fenofibric acid, an active metabolite of fenofibrate, after single oral administration of FF-BGL was more than 3 times higher than that of, fenofibrate, in accordance. In fasting rats, plasma concentration of fenofibric acid after fenofibrate administration was curtailed into less than half of that in ad libitum-fed rats, while FF-BGL, showed about the same plasma level even in the starving rats. This is the first report showing that BGL-prodrug improves pharmacological and pharmacokinetic properties as well as hydrophilicity of highly hydrophobic compounds. Furthermore, prodrug strategy using BGL suggests the possibility of diminishing the food drug interaction effects, which should be advantageous for promoting drug compliance. BGL will be a suitable prodrug strategy to ameliorate physical, pharmacological, and pharmacokinetic characteristics of extremely hydrophobic compounds.

リンク情報
DOI
https://doi.org/10.1021/mp400133j
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23672178
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000321472000021&DestApp=WOS_CPL
ID情報
  • DOI : 10.1021/mp400133j
  • ISSN : 1543-8384
  • PubMed ID : 23672178
  • Web of Science ID : WOS:000321472000021

エクスポート
BibTeX RIS